Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08DK002280-03
Application #
2134150
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Project Start
1994-04-20
Project End
1999-03-31
Budget Start
1996-04-01
Budget End
1997-03-31
Support Year
3
Fiscal Year
1996
Total Cost
Indirect Cost

  Institution

Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02215

  Publications

Cohen, H T; Zhou, M; Welsh, A M et al. (1999) An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association. Biochem Biophys Res Commun 266:43-50
Knebelmann, B; Ananth, S; Cohen, H T et al. (1998) Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Cancer Res 58:226-31
Mukhopadhyay, D; Knebelmann, B; Cohen, H T et al. (1997) The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 17:5629-39
Cohen, H T; Bossone, S A; Zhu, G et al. (1997) Sp1 is a critical regulator of the Wilms' tumor-1 gene. J Biol Chem 272:2901-13